Clinical trials
GLP-1 clinical trials
Below are recruiting glp-1 clinical trials, each written for real people, not researchers. We’re tracking 94 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT07652333Recruiting
Strength training for muscle and mind on obesity medication
This study tests whether strength training can help adults taking new obesity medications (like Wegovy or Ozempic) maintain muscle and improve mental health. You would start the medication after your first study visit.
Pittsburgh, PennsylvaniaAges 18 years+ - NCT07653412Recruiting
Genetic test for predicting weight loss drug response
This trial looks at whether your genes can predict how well you will respond to weight loss medications like semaglutide (Wegovy/Ozempic) or tirzepatide (Mounjaro). It may help doctors choose the right drug for you based on your DNA.
AthensAges 18 years+ - NCT07633639Recruiting
GLP-1 Medicine After Weight-Loss Surgery in Chinese Patients
This trial tests whether adding a GLP-1 medication (a type of diabetes and weight-loss drug) after weight-loss surgery helps patients with obesity and related health conditions like diabetes. Researchers want to see if combining surgery with this medicine works better than surgery alone.
BeijingAges 18–60 - NCT07627191RecruitingEarly Phase 1
GLP-1 drug plus standard chemo for first-line advanced cancers
This trial tests whether adding a GLP-1 receptor agonist (a drug used for diabetes and weight loss) to standard chemotherapy can help people with advanced pancreatic, colorectal, or liver cancer. It is for people who have not yet started treatment for their metastatic disease and have a BMI of 25 or higher.
Tucson, ArizonaAges 18–99 - NCT07607587RecruitingPhase 1
Testing a new weight-loss drug for people who couldn't tolerate GLP-1 shots
This study tests a new injectable medication called cagrilintide for people with obesity who had to stop GLP-1 drugs (like Ozempic or Wegovy) because of stomach problems. The goal is to see if cagrilintide causes fewer stomach side effects while still helping with weight.
Walnut Creek, CaliforniaAges 18 years+ - NCT07518407Recruiting
Nutrition Education and Diet Guidance While Using GLP-1 Medication
This study teaches adults on GLP-1 medication (like Ozempic or Wegovy) how to eat better and lose weight using a smartphone app. Researchers want to see if personalized nutrition advice helps you get better results from your medication.
Columbia, South CarolinaAges 18–65 - NCT07502508RecruitingPhase 2
Icovamenib for type 2 diabetes with Ozempic
This trial tests an investigational pill called icovamenib for people with type 2 diabetes who are already on Ozempic but still have high blood sugar. The goal is to see if adding icovamenib helps lower blood sugar more safely.
Birmingham, AlabamaAges 18–70 - NCT07506356Recruiting
Stomach emptying in diabetes patients on GLP-1 drugs
This study uses an ultrasound to check how fast your stomach empties food. It looks at people with type 2 diabetes who have been taking a GLP-1 medication for at least three months.
Geneva, Canton of GenevaAges 18 years+ - NCT07495904Recruiting
Weight loss drug effects on body muscle with extra protein
This trial tests a weight-loss medication (GLP-1 receptor agonist) combined with dietary protein to see if it helps protect muscle while losing fat. It is for adults with obesity who are not taking certain other medications or supplements.
HeraklionAges 30–65 - NCT07484061Recruiting
Drinkable supplement for hair loss in women on weight-loss drugs
This trial tests if a special drinkable supplement can help prevent or reduce hair loss in women who are taking a GLP-1 or GIP receptor agonist (a type of weight-loss or diabetes medication). The study looks for women who have just started this medication or have been on it for less than 3 months.
Madrid, MadridAges 35 years+ - NCT07480109Recruiting
More protein while on weight-loss meds in women
This study tests if eating extra protein helps middle-aged women with overweight or obesity who are just starting a GLP-1 medication. You would eat extra protein for a few weeks while staying active as usual.
Austin, TexasAges 30–60 - NCT07478198Enrolling by invitation
PLLA injections for facial sagging after weight loss drug use
This trial tests whether PLLA injections can safely improve facial sagging in people who lost weight on GLP-1 drugs. If you are between 30 and 60, have noticeable sagging or smile lines, and have not had other facial treatments recently, this may be an option.
Shanghai, Shanghai MunicipalityAges 30–60 - NCT07428746RecruitingPhase 3
GLP-1 drug for bone health in older women with diabetes
This study tests whether a diabetes medication called a GLP-1 receptor agonist can help improve bone and muscle health in older women with type 2 diabetes who are at risk for osteoporosis. It aims to see if the drug can strengthen bones and prevent falls.
Atlanta, GeorgiaAges 65 years+ - NCT07419854RecruitingPhase 4
Restoring facial fullness after GLP-1 weight loss with Radiesse
This trial tests whether a facial filler called Radiesse can restore volume lost during weight loss from GLP-1 medications (like Wegovy or Mounjaro). It's for adults just starting GLP-1 therapy who expect to lose 20 pounds or more and want to see if fillers can help their face look fuller.
Pasadena, CaliforniaAges 21–65 - NCT07393360Recruiting
Muscle preservation during weight loss with GLP-1 drugs
This trial tests a special medical food to help keep muscle mass while losing weight with GLP-1 medications like liraglutide, semaglutide, or tirzepatide. It's for adults with obesity or overweight with related health issues.
MilanAges 18–65 - NCT07307235RecruitingPhase 4
Comparing a new diabetes combination to standard care for type 2 diabetes
This trial tests if a once-daily injectable combination (iGlarLixi) helps control blood sugar better than usual care for people with type 2 diabetes who are already taking diabetes pills. It aims to find a more effective treatment option.
Hefei, AnhuiAges 18 years+ - NCT07295223RecruitingPhase 3
GLP-1 and SGLT2 drugs for heart attack recovery
This trial tests if combining GLP-1 and SGLT2 medications can reduce inflammation and improve heart function after a heart attack in people with type 2 diabetes and obesity. It looks for patients with a specific type of heart attack, elevated CRP levels, and preserved heart pumping ability.
León, GuanajuatoAges 18 years+ - NCT06734312Recruiting
Stomach procedure to maintain weight loss after GLP-1s
This study is for people who have lost weight using semaglutide or tirzepatide and are stopping that medication. It tests a stomach procedure (called mucosal ablation) to see if it can help you keep the weight off after stopping the drug.
Cary, North CarolinaAges 21–65 - NCT07272837Recruiting
How semaglutide affects heart and muscle mass
This study looks at how semaglutide (Ozempic or Wegovy) changes heart muscle and body muscle. It may help people with type 2 diabetes or those taking the drug for weight loss understand if their heart is affected.
Edmonton, AlbertaAges 18–80 - NCT07244445Recruiting
Pistachios with GLP-1 therapy for weight and nutrition
This study tests whether adding pistachios to your diet can improve nutrition and weight loss while you are already on a GLP-1 medication like Wegovy, Ozempic, or Mounjaro. It is open to adults who have been on the medication for at least three months.
Clevland, OhioAges 18–80 - NCT07229170Recruiting
Taste changes and eating habits on weight loss drugs
This study looks at how GLP-1 medications (like semaglutide/Wegovy or tirzepatide/Mounjaro) change your sense of taste and eating habits while losing weight. If you are 18–60, have obesity, and have been taking one of these drugs for at least 12 weeks, you may qualify.
Roma, ItalyAges 18–60 - NCT07224334RecruitingPhase 1
How cells talk to adjust insulin for weight
This study looks at how cells in the pancreas communicate to help the body produce enough insulin when you have insulin resistance (weight-related). It tests a peptide to see how this communication works.
Durham, North CarolinaAges 18–60 - NCT07225816RecruitingPhase 1
How fasting affects stomach food with GLP-1 drugs
This study looks at how long fasting and temporarily stopping certain diabetes or weight-loss medications (like semaglutide or liraglutide) affects how much food stays in your stomach. It may help understand how these medications work in people who are overweight.
Cypress, CaliforniaAges 18 years+ - NCT07221214RecruitingPhase 2
Testing a diabetes drug for drinking and heart health in HIV
This trial tests if a once-weekly diabetes medication (semaglutide) can help people with HIV reduce heavy drinking and improve heart health. It's for people who drink alcohol and have a higher body weight.
Nashville, TennesseeAges 18–89
Hear when a new GLP-1 trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for glp-1?
- Yes. Clin2 currently lists 94 recruiting glp-1 studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a glp-1 trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a glp-1 trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.